Copy to clipboard 
CONMED reported 2Q25 orthopedic sales of $140.7 million, up 0.9% compared to the second quarter of 2024. For the first half of 2025, the company generated $279 million in orthopedic sales, up 1.7% compared to the prior year.
This year, CONMED is focused on three objectives to get its orthopedics business back on track: stabilizing and scaling operations, driving efficiencies with the help of a consulting firm and finally building a high performance supply chain. The company has lost ground to competitors over the last several quarters, though.
“Our growth is lower than the actual market growth,” said CONMED CEO Pat Beyer. “From a pure number standpoint, we’ve lost market share. The good news is with a platform like BioBrace, we’re still driving forward and we’re on offense there. We’re continuing to be seen as an innovative orthopedic company globally. We have lost market share this year. The numbers say that. On the other side, our innovation from new products continues to roll out and our BioBrace platform continues to put us in a good position going forward.”
BioBrace drove double digit growth in the second quarter and is now in clinical use across 52 distinct procedures, including rotator cuff and ACL repairs as well as Achilles and gluteus medius reconstructions. CONMED’s foot and ankle business has also been a bright spot, notching its third consecutive quarter of double-digit growth.
The company narrowed its total revenue guidance range to between $1.365 billion and $1.378 billion.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Trauma | $12.1 | $11.0 | $1.1 | 10% |
| Sports Medicine | $128.6 | $128.5 | $0.1 | 0.1% |
| Total | $140.7 | $139.5 | $1.2 | 0.9% |
| Segment | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| Trauma | $25.4 | $23.0 | $2.4 | 10.5% |
| Sports Medicine | $253.6 | $251.5 | $2.1 | 0.8% |
| Total | $279.0 | $274.4 | $4.5 | 1.7% |
Orthopedic Sales by Geography
| Region | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $51.7 | $52.1 | ($0.4) | (0.8%) |
| OUS | $89.0 | $87.4 | $1.6 | 1.9% |
| EMEA | $35.6 | $35.0 | $0.6 | 1.6% |
| APAC | $31.7 | $31.2 | $0.5 | 1.6% |
| ROW | $21.7 | $21.2 | $0.6 | 2.6% |
| Total | $140.7 | $139.5 | $1.2 | 0.9% |
| Region | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $104.2 | $106.3 | ($2.1) | (1.9%) |
| OUS | $174.8 | $168.2 | $6.6 | 3.9% |
| EMEA | $71.5 | $68.2 | $3.3 | 4.9% |
| APAC | $58.7 | $57.5 | $1.2 | 2.2% |
| ROW | $44.5 | $42.5 | $2.0 | 4.8% |
| Total | $279.0 | $274.4 | $4.5 | 1.7% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $342.3 | |
| Cost of Sales | $154.0 | 45% |
| Selling and Admin | $136.0 | 39.7% |
| R&D | $14.1 | 4.1% |
| R&D | $14.1 | 4.1% |
| Other | $16.7 | 4.9% |
CONMED reported 2Q25 orthopedic sales of $140.7 million, up 0.9% compared to the second quarter of 2024. For the first half of 2025, the company generated $279 million in orthopedic sales, up 1.7% compared to the prior year.
This year, CONMED is focused on three objectives to get its orthopedics business back on track: stabilizing and...
CONMED reported 2Q25 orthopedic sales of $140.7 million, up 0.9% compared to the second quarter of 2024. For the first half of 2025, the company generated $279 million in orthopedic sales, up 1.7% compared to the prior year.
This year, CONMED is focused on three objectives to get its orthopedics business back on track: stabilizing and scaling operations, driving efficiencies with the help of a consulting firm and finally building a high performance supply chain. The company has lost ground to competitors over the last several quarters, though.
“Our growth is lower than the actual market growth,” said CONMED CEO Pat Beyer. “From a pure number standpoint, we’ve lost market share. The good news is with a platform like BioBrace, we’re still driving forward and we’re on offense there. We’re continuing to be seen as an innovative orthopedic company globally. We have lost market share this year. The numbers say that. On the other side, our innovation from new products continues to roll out and our BioBrace platform continues to put us in a good position going forward.”
BioBrace drove double digit growth in the second quarter and is now in clinical use across 52 distinct procedures, including rotator cuff and ACL repairs as well as Achilles and gluteus medius reconstructions. CONMED’s foot and ankle business has also been a bright spot, notching its third consecutive quarter of double-digit growth.
The company narrowed its total revenue guidance range to between $1.365 billion and $1.378 billion.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Trauma | $12.1 | $11.0 | $1.1 | 10% |
| Sports Medicine | $128.6 | $128.5 | $0.1 | 0.1% |
| Total | $140.7 | $139.5 | $1.2 | 0.9% |
| Segment | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| Trauma | $25.4 | $23.0 | $2.4 | 10.5% |
| Sports Medicine | $253.6 | $251.5 | $2.1 | 0.8% |
| Total | $279.0 | $274.4 | $4.5 | 1.7% |
Orthopedic Sales by Geography
| Region | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $51.7 | $52.1 | ($0.4) | (0.8%) |
| OUS | $89.0 | $87.4 | $1.6 | 1.9% |
| EMEA | $35.6 | $35.0 | $0.6 | 1.6% |
| APAC | $31.7 | $31.2 | $0.5 | 1.6% |
| ROW | $21.7 | $21.2 | $0.6 | 2.6% |
| Total | $140.7 | $139.5 | $1.2 | 0.9% |
| Region | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $104.2 | $106.3 | ($2.1) | (1.9%) |
| OUS | $174.8 | $168.2 | $6.6 | 3.9% |
| EMEA | $71.5 | $68.2 | $3.3 | 4.9% |
| APAC | $58.7 | $57.5 | $1.2 | 2.2% |
| ROW | $44.5 | $42.5 | $2.0 | 4.8% |
| Total | $279.0 | $274.4 | $4.5 | 1.7% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $342.3 | |
| Cost of Sales | $154.0 | 45% |
| Selling and Admin | $136.0 | 39.7% |
| R&D | $14.1 | 4.1% |
| R&D | $14.1 | 4.1% |
| Other | $16.7 | 4.9% |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
